Study guide

4.5 Survivorship Care Planning & Late Effects Management

Advanced Oncology Certified Nurse Practitioner AOCNP

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Overview

1.1 About the AOCNP Exam 1.2 How to Use This AOCNP Study Guide

2 Chapter 2: Cancer Continuum - Risk, Prevention & Screening

2.1 Cancer Risk Factors, At-Risk Populations & Health Disparities 2.2 Primary Prevention, Vaccination, Chemoprevention & Risk-Reducing Surgery 2.3 Cancer Screening & Early Detection Guidelines 2.4 Screening for Subsequent & Second Primary Malignancies 2.5 Hereditary Cancer Syndromes & Genetic Counseling

3 Chapter 3: Cancer Continuum - Assessment, Diagnosis & Staging

3.1 Diagnostic Workup, Tissue Biopsy & Biomarker Evaluation 3.2 Pathology Interpretation, Histology & Tumor Grading 3.3 Cancer Staging Systems (TNM) & Prognostication Models 3.4 Performance Status, Frailty & Geriatric Assessment

4 Chapter 4: Cancer Continuum - Planning, Coordination & Survivorship

4.1 Established Guidelines for Care & Categories of Evidence 4.2 Individualized Treatment Planning & Molecular Tumor Boards 4.3 Reproductive Planning & Fertility Preservation 4.4 Patient Navigation & Interprofessional Care Coordination 4.5 Survivorship Care Planning & Late Effects Management 4.6 Post-Treatment Surveillance for Cancer Recurrence

5 Chapter 5: Cancer Treatment - Antineoplastic Pharmacology & Chemotherapy

5.1 Antineoplastic Principles, Dosing & Dose Adjustments 5.2 Cytotoxic Chemotherapy Classes & Adverse Effect Management 5.3 Safe Administration, Handling & Infusion Toxicities 5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring

6 Chapter 6: Cancer Treatment - Targeted, Immuno & Hormonal Therapies

6.1 Targeted Therapies, Tyrosine Kinase Inhibitors & ADCs 6.2 Cancer Immunotherapy, Checkpoint Inhibitors & CAR T-Cell Therapy 6.3 Endocrine & Hormonal Therapies in Oncology

7 Chapter 7: Cancer Treatment - Radiation, Surgery, Regional & Multimodal Therapy

7.1 Radiation Oncology Principles & Toxicity Management 7.2 Surgical Oncology, Perioperative Care & Reconstruction 7.3 Regional & Localized Therapy Administration 7.4 Multimodal Therapy & Treatment Sequencing 7.5 Complementary, Alternative & Integrative Therapies

8 Chapter 8: Cancer Treatment - Transplantation, Clinical Trials & Response

8.1 Hematopoietic Stem Cell Transplantation (HSCT) & Cell Therapy 8.2 Clinical Trials, Research Protocols & Response Evaluation (RECIST)

9 Chapter 9: Supportive Care - Pain & Controlled Substance Safety

9.1 Cancer Pain Assessment & Comprehensive Analgesic Management 9.2 Controlled Substance Safety & Opioid Stewardship 9.3 Nonpharmacologic & Integrative Symptom Interventions

10 Chapter 10: Supportive Care - Symptom & Comorbidity Management

10.1 Acute, Late & Long-Term Patterns of Treatment-Related Symptoms 10.2 Gastrointestinal Symptom Management (CINV, Mucositis, Diarrhea) 10.3 Hematologic & Neurologic Toxicity Management 10.4 Dermatologic, Metabolic & Fatigue Management 10.5 Cancer-Associated Thrombosis & Anticoagulation 10.6 Comorbid Conditions & Their Interaction With Cancer Treatment 10.7 Palliative Care, Hospice & End-of-Life Management

11 Chapter 11: Oncologic Emergencies

11.1 Superior Vena Cava Syndrome & Structural Emergencies 11.2 Spinal Cord Compression & Neurologic Emergencies 11.3 Metabolic Emergencies: Tumor Lysis Syndrome & Hypercalcemia of Malignancy 11.4 Febrile Neutropenia, Sepsis & Vesicant Extravasation 11.5 Cardiopulmonary & Airway Emergencies 11.6 Hematologic & Endocrine Emergencies: DIC, Leukostasis, Hyperviscosity & SIADH

12 Chapter 12: Psychosocial Issues

12.1 Psychosocial Assessment & Distress Screening in Oncology 12.2 Risk Factors & At-Risk Oncology Populations 12.3 Psychosocial & Emotional Sequelae of Disease and Treatment 12.4 Psychiatric & Psychosocial Comorbidities in Cancer Care 12.5 Caregiver Burden, Support & Community Resources

13 Chapter 13: Professional Practice & Roles of the APRN

13.1 APRN Scope of Practice, Prescriptive Authority & Standards of Care 13.2 Bioethics, Informed Consent & Quality Improvement in Oncology 13.3 Cultural Competence, Implicit Bias & Equitable Oncology Care 13.4 Accreditation Standards & Outcomes of APRN Practice 13.5 Competency Evaluation, Peer Review & Peer Education

4.5 Survivorship Care Planning & Late Effects Management

Key Takeaways Explain This Topic AI

Survivorship Care Plans (SCPs) must be delivered upon completion of curative-intent treatment and synthesize treatment history, potential late organ toxicities, recommended surveillance schedules, and health promotion strategies based on ASCO/NCCN guidelines.

Anthracycline chemotherapy (doxorubicin, epirubicin) causes dose-dependent cumulative cardiotoxicity, requiring baseline and surveillance echocardiography (LVEF assessment) and lifelong monitoring for congestive heart failure.

Chest radiation therapy increases risks for secondary breast cancer, coronary artery disease, and carotid artery stenosis, necessitating annual breast MRI/mammography starting 8-10 years post-radiation (or age 25) and aggressive cardiovascular risk modification.

Late endocrine toxicities after pelvic radiation or alkylating agents include premature ovarian insufficiency, infertility, hypogonadism, and accelerated bone density loss requiring DEXA monitoring and risk mitigation.

Cancer-related fatigue (CRF) and chemotherapy-induced peripheral neuropathy (CIPN) represent chronic survivorship challenges; CRF responds best to structured aerobic exercise, while CIPN requires duloxetine as first-line pharmacotherapy.

Last updated: August 2026

2.2 Cancer Survivorship Care Planning & Late Effects Management

Clinical Pearl: Long-term toxicity monitoring requires understanding the distinction between acute, long-term, and late adverse effects. Acute effects occur during therapy and resolve upon drug clearance; long-term effects begin during treatment and persist post-therapy (e.g., CIPN); late effects manifest months to decades after therapy completion (e.g., radiation-induced secondary malignancies or anthracycline cardiomyopathy).

Principles of Survivorship Care & Care Plan Delivery

Cancer survivorship begins at the time of diagnosis and continues throughout the balance of life. Upon completing primary curative-intent antineoplastic therapy, patients undergo a critical care transition. As established by the National Academy of Medicine (formerly IOM), American Society of Clinical Oncology (ASCO), and Commission on Cancer (CoC), every survivor must be provided a comprehensive Survivorship Care Plan (SCP) .

Essential Components of a Survivorship Care Plan

Treatment Summary: Detailed documentation of cancer diagnosis, stage, histology, surgery performed, specific chemotherapy agents (including cumulative doses of anthracyclines and alkylating agents), radiation therapy parameters (total dose, fractions, anatomical fields), targeted agents, biologic therapies, and major acute complications.

Follow-Up & Surveillance Schedule: Clear timelines for oncology follow-up visits, diagnostic imaging, lab work, endoscopic surveillance, and tumor markers tailored to recurrence risk windows.

Late Toxicity Monitoring: Explicit guidance regarding organ-specific late toxicities based on prior exposure history.

Health Promotion & Risk Reduction: Guidelines for physical activity, nutrition, smoking cessation, alcohol limitation, sun protection, and immunizations.

Care Coordination: Explicit assignment of responsibilities between oncology specialist care and primary care providers.

Organ-Specific Late Toxicities & Surveillance Guidelines

Organ System Causative Antineoplastic / Radiotherapy Exposure Clinical Manifestation / Late Toxicity Diagnostic Workup & Surveillance Protocol

Cardiovascular Anthracyclines ( doxorubicin >450–550 mg/m²), Trastuzumab , Chest/Mantle Radiotherapy Left ventricular dysfunction, cardiomyopathy, heart failure, premature coronary artery disease, valvular damage Baseline & post-treatment Echocardiogram (LVEF); lipid panel & BP management; stress testing if symptomatic

Pulmonary Bleomycin (cumulative >400 units), Busulfan , Carmustine (BCNU), Thoracic Radiotherapy Pulmonary fibrosis, chronic pneumonitis, restrictive lung disease, impaired gas diffusion Baseline & post-treatment Pulmonary Function Tests (PFTs with DLCO); high-resolution chest CT if symptomatic

Neurologic Platinums ( cisplatin , oxaliplatin ), Taxanes ( paclitaxel , docetaxel ), Vincristine , Cranial Radiotherapy Chemotherapy-induced peripheral neuropathy (CIPN), neurocognitive dysfunction ("chemobrain"), radionecrosis Clinical sensory/motor neuro exams; duloxetine for painful CIPN; cognitive rehabilitation & neuropsych testing

Endocrine & Bone Alkylating agents ( cyclophosphamide ), Pelvic RT, Aromatase Inhibitors, LHRH agonists Premature ovarian insufficiency, infertility, hypogonadism, secondary osteoporosis, metabolic syndrome Serum FSH/estradiol/testosterone; baseline & serial DEXA scan (Q2 years); calcium + vitamin D3 supplementation

Renal & Urinary Cisplatin , Ifosfamide (Fanconi syndrome), High-dose Methotrexate , Pelvic Radiotherapy Chronic kidney disease (CKD), glomerular filtration decline, hemorrhagic cystitis, radiation cystitis Serial serum creatinine, eGFR, BUN, electrolyte panels, urinalysis; nephrology referral if eGFR <60 mL/min

Secondary Malignancy Alkylating agents, Epipodophyllotoxins ( etoposide ), Ionizing Radiation Therapy-related Myelodysplastic Syndrome / Acute Myeloid Leukemia (t-MDS/t-AML), secondary solid tumors Annual CBC; high-risk breast screening (MRI/mammography) for mantle RT; age/risk-appropriate screening

  • Late Toxicities of Radiation Therapy & Systemic Therapies
  • Cardiovascular Toxicity

Anthracycline-induced cardiotoxicity results from topoisomerase II-beta cleavage and reactive oxygen species generation, causing irreversible cardiomyocyte loss and myocyte vacuolization. Risk correlates strictly with cumulative dose ( doxorubicin threshold 450–550 mg/m²; epirubicin 900 mg/m²). Thoracic radiation accelerates coronary artery atherosclerosis, pericardial constriction, and conduction defects. Combined exposure to anthracyclines and chest radiation multiplies cardiac failure risk.

Secondary Malignancies

Secondary primary cancers account for approximately 18% of all cancer diagnoses in the United States.

Therapy-Related Myeloid Malignancies (t-MDS/t-AML): Alkylating agents ( cyclophosphamide , melphalan ) induce t-MDS/t-AML with a characteristic latency of 5–7 years, frequently associated with deletions of chromosome 5 or 7. Topoisomerase II inhibitors ( etoposide , doxorubicin ) induce t-AML with a shorter latency (1–3 years), typically characterized by 11q23 ( MLL gene) balanced translocations.

Radiation-Induced Solid Tumors: Radiation-induced solid tumors (e.g., breast, lung, thyroid, sarcoma, non-melanoma skin cancer) occur within or adjacent to prior radiation fields, with a minimum latency period of 10 to 30 years . Women receiving mantle radiation for Hodgkin lymphoma before age 30 carry a cumulative lifetime breast cancer risk approaching 30%–40%. Radiation Exposure (e.g., Mantle Field <30 yrs old)

  • │
  • ▼ Latency Period (8-10 Years)
  • DNA Double-Strand Damage & Genomic Instability
  • │
  • ▼ High Risk Window (Age 25+ or 8-10 yrs post-RT)

Initiate Dual Screening Protocol:

  • ├─ Annual Contrast-Enhanced Breast MRI
  • └─ Annual Digital Mammography
  • Management of Chronic Survivorship Symptoms
  • Cancer-Related Fatigue (CRF)

CRF is a distressing, persistent, subjective sense of physical, emotional, or cognitive tiredness related to cancer or treatment that is not proportional to recent activity and interferes with usual functioning.

Workup: Evaluate for treatable underlying etiologies: anemia, thyroid dysfunction, sleep apnea, depression, nutritional deficiencies, and pain.

Interventions: Structured aerobic physical activity (e.g., 150 minutes/week of moderate intensity exercise) possesses the highest level of empirical evidence (Category 1) for reducing CRF. Psychosocial interventions (Cognitive Behavioral Therapy for Fatigue [CBT-F]) are highly effective. Pharmacologic agents (e.g., methylphenidate, modafinil) show limited benefit and are reserved for select advanced cases.

Chemotherapy-Induced Peripheral Neuropathy (CIPN)

CIPN presents as a stocking-glove distribution of sensory loss, paresthesias, dysesthesias, and neuropathic pain.

First-Line Therapy: Duloxetine (60 mg once daily) is the only pharmacologic agent recommended by ASCO guidelines with high-quality randomized evidence for painful CIPN.

Non-Pharmacologic Support: Physical therapy, balance training, occupational safety modifications, and fall prevention protocols.

Cancer-Related Cognitive Impairment (CRCI / "Chemobrain")

Deficits in executive function, working memory, processing speed, and verbal fluency affect 20%–30% of post-chemotherapy survivors. Management emphasizes neuropsychological evaluation, cognitive rehabilitation strategies, mindfulness-based stress reduction (MBSR), and treating co-morbid sleep disturbance or distress.

Loading diagram... Post-Treatment Survivorship Surveillance & Organ Toxicities Algorithm